PURPOSE OF REVIEW: To highlight recent evidence from the clinical trials of anti-tumor necrosis factor (TNF) and non anti-TNF biologics for rheumatoid arthritis (RA) focused on comparative clinical efficacy including safety outcomes and medication discontinuation. RECENT FINDINGS: Patients with RA are sometimes able to attain low disease activity or remission since the introduction of biologic therapy for RA. Biologics like anti-TNF, anti-interleukin-6 (IL-6), anti-CD20 and those that modulate T-cell co-stimulation have consistently shown good efficacy in patients with RA. Preliminary data from comparative efficacy studies to evaluate the potential differences between anti-TNF and non anti-TNF biologics have shown little differences among these. There is ongoing work in comparative efficacy to answer this question further. SUMMARY: Biologic therapy in RA has significantly changed the course of RA in the last decade. Recently published clinical trials have been focused on comparative efficacy, cardiovascular safety of biologics and potential anti-TNF therapy discontinuation in patients with RA.
PURPOSE OF REVIEW: To highlight recent evidence from the clinical trials of anti-tumor necrosis factor (TNF) and non anti-TNF biologics for rheumatoid arthritis (RA) focused on comparative clinical efficacy including safety outcomes and medication discontinuation. RECENT FINDINGS:Patients with RA are sometimes able to attain low disease activity or remission since the introduction of biologic therapy for RA. Biologics like anti-TNF, anti-interleukin-6 (IL-6), anti-CD20 and those that modulate T-cell co-stimulation have consistently shown good efficacy in patients with RA. Preliminary data from comparative efficacy studies to evaluate the potential differences between anti-TNF and non anti-TNF biologics have shown little differences among these. There is ongoing work in comparative efficacy to answer this question further. SUMMARY: Biologic therapy in RA has significantly changed the course of RA in the last decade. Recently published clinical trials have been focused on comparative efficacy, cardiovascular safety of biologics and potential anti-TNF therapy discontinuation in patients with RA.
Authors: M J H Boumans; J G A Houbiers; P Verschueren; H Ishikura; R Westhovens; E Brouwer; B Rojkovich; S Kelly; M den Adel; J Isaacs; H Jacobs; J Gomez-Reino; G M Holtkamp; A Hastings; D M Gerlag; P P Tak Journal: Ann Rheum Dis Date: 2011-09-14 Impact factor: 19.103
Authors: Charlotte L Krieckaert; Anna Jamnitski; Michael T Nurmohamed; Piet J Kostense; Maarten Boers; Gertjan Wolbink Journal: Arthritis Rheum Date: 2012-12
Authors: E Hurt-Camejo; S Paredes; L Masana; G Camejo; P Sartipy; B Rosengren; J Pedreno; J C Vallve; P Benito; O Wiklund Journal: Arthritis Rheum Date: 2001-12
Authors: S M van der Kooij; Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; M Güler-Yüksel; A H Zwinderman; P J S M Kerstens; P A H M van der Lubbe; W M de Beus; B A M Grillet; H K Ronday; T W J Huizinga; F C Breedveld; B A C Dijkmans; C F Allaart Journal: Ann Rheum Dis Date: 2008-07-28 Impact factor: 19.103
Authors: Paresh Jobanputra; Fiona Maggs; Alison Deeming; David Carruthers; Elizabeth Rankin; Alison C Jordan; Abdul Faizal; Carolyn Goddard; Mark Pugh; Simon J Bowman; Sue Brailsford; Peter Nightingale Journal: BMJ Open Date: 2012-11-12 Impact factor: 2.692
Authors: Arthur Kavanaugh; Roy M Fleischmann; Paul Emery; Hartmut Kupper; Laura Redden; Benoit Guerette; Sourav Santra; Josef S Smolen Journal: Ann Rheum Dis Date: 2012-05-05 Impact factor: 19.103
Authors: M Schiff; M Keiserman; C Codding; S Songcharoen; A Berman; S Nayiager; C Saldate; T Li; R Aranda; J-C Becker; C Lin; P L N Cornet; M Dougados Journal: Ann Rheum Dis Date: 2007-11-29 Impact factor: 19.103
Authors: Bruce Kirkham; Khaldoun Chaabo; Christopher Hall; Toby Garrood; Timothy Mant; Elizabeth Allen; Alexandra Vincent; Joana C Vasconcelos; Andrew T Prevost; Gabriel S Panayi; Valerie M Corrigall Journal: Rheumatology (Oxford) Date: 2016-08-07 Impact factor: 7.580
Authors: Fernanda S Tonin; Laiza M Steimbach; Leticia P Leonart; Vinicius L Ferreira; Helena H Borba; Thais Piazza; Ariane G Araújo; Fernando Fernandez-Llimos; Roberto Pontarolo; Astrid Wiens Journal: Eur J Clin Pharmacol Date: 2018-07-18 Impact factor: 2.953
Authors: Dimitrios A Pappas; Robert A Gerber; Heather J Litman; David Gruben; Jamie Geier; Winnie D Hua; Connie Chen; Youfu Li; Joel M Kremer; John S Andrews; Jeffrey A Bourret Journal: Am Health Drug Benefits Date: 2018-05